Loading company…
TRex Bio develops therapies for immune-mediated diseases using human tissue analysis.
Founded in 2018 and based in San Francisco, US, TRex Bio uses human tissue analysis, sequencing, and computational tools to discover therapies for immune-mediated diseases. In January 2026, it raised USD 50 million in venture funding from Janus Henderson Investors, Balyasny Asset Management L.P., Affinity Asset Advisors, Alexandria Venture Investments, Avego, Delos Capital, Eli Lilly & Company, Johnson & Johnson Innovation, Pfizer Venture Investments, Polaris Partners, and SV Health Investors. The funding will support clinical work and early-stage programs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in